is a specific blocker of voltage-gated potassium channels (K V 1 family) clinically approved for the symptomatic treatment of patients with multiple sclerosis (MS). It has recently been shown that [ 18 F]3F4AP, a radiofluorinated analog of 4AP, also binds to K V 1 channels and can be used as a PET tracer for the detection of demyelinated lesions in rodent models of MS. Here, we investigate three novel 4AP derivatives containing methyl (-CH 3 ), methoxy (-OCH 3 ) and trifluoromethyl (-CF 3 ) in the 3 position as potential candidates for PET imaging and/or therapy. We characterized the physicochemical properties of these compounds (pK a and logD) and analyzed their ability to block Shaker K + channel under different voltage and pH conditions. Our results demonstrate that all three derivatives are able to block voltage-gated potassium channels. Specifically, 3-methyl-4-aminopyridine (3Me4AP) was found to be approximately 7-fold more potent than 4AP, whereas the methoxy (3MeO4AP) and trifluoromethyl (3CF 3 4AP) containing compounds were about 3-to 4-fold less potent than 4AP, respectively. These results suggest that these novel derivatives are potential candidates for therapy and imaging.
Introduction
In normally myelinated neurons, voltage-gated potassium (K + ) channels K v 1.1 and K v 1.2 are clustered near the nodes of Ranvier beneath the myelin sheath 1, 2 . Upon demyelination, these channels become exposed, migrate through the demyelinated segment and concomitantly increase in expression several fold [3] [4] [5] [6] [7] [8] [9] . This aberrant redistribution of K + channels impairs conduction of action potentials, which leads to neurological deficits 3,10-14 . 4-aminopyridine (4AP) is a selective blocker of K v channels [15] [16] [17] [18] [19] [20] [21] used clinically to improve neurological conduction in people with multiple sclerosis (MS) [22] [23] [24] [25] [26] and other demyelinating diseases 27, 28 . Mechanistically, 4AP blocks the exposed K + channels and therefore enhances conduction 16, 17, 19, 20, [29] [30] [31] [32] . Recently, it has been shown that the fluorinated derivative 3-fluoro-4-aminopyridine (3F4AP) also binds to these channels 33 and, once labeled with 18 F, can serve to detect areas of demyelination using positron emission tomography (PET) [33] [34] [35] [36] [37] . Given the potential of these molecules as therapeutic and imaging agents, we set out to investigate three new 4AP derivatives and their structure-activity relationships.
Prior work on the structure-activity relationship studies of 4AP derivatives has shown that small modifications on the 3 position are permitted 33, [38] [39] [40] and that the in vivo potency is highly correlated with the pK a 29, 31 . 4AP and derivatives are basic compounds that exist in the protonated or neutral form depending on the pH of the medium (Fig. 1) .
The protonated form mimics a large K + ion and is required to block the channel 41 , while the neutral form is required for the drug to get across the blood-brain barrier (BBB) 42 .
Therefore, a pK a near the physiological pH is ideal. In addition, the pharmacokinetic properties are largely dependent on the lipophilicity and pK a of these molecules. For example, 4AP has a pK a of 9.6, resulting in high potency but slow penetration into the CNS, which explains why a slow release formulation is required for therapy 22, 23, 43 .
3F4AP, on the other hand, has a pK a of 7.6 which results in much faster CNS penetration and good favorability for PET imaging 33 39, 45 but that has minimal permeability to the BBB and requires intrathecal administration.
Fig. 1. Acid-base equilibrium of 4-aminopyridine derivatives
Given the correlations between the pK a , lipophilicity and molecular size with in vivo activity, we hypothesized that the derivatives 3-methyl-4-aminopyridine (3Me4AP),
3-methoxy-4-aminopyridine (3MeO4AP) and
3-trifluoromethyl-4-aminopyridine (3CF 3 4AP) would be permeable to the CNS and be suitable candidates for therapy and/or imaging (Figure 2A) . These molecules are particularly interesting as potential PET radioligands since they are amenable to labeling with 11 C, which provides some advantages over 18 F-labeled radioligands. While 11 C has a significantly shorter half-life compared to 18 F (20 vs. 110 min) limiting its use to sites with a cyclotron, 11 C-labeled tracers tend to be easier to radiolabel and their short half-life allows for multiple scans on the same subject and day. In fact, we recently communicated methods to produce 46 .
Methods

pK a determination
The pK a of each compound was measured by acid titration. Briefly, 5 mg of each compound were dissolved in 5 mL of water and titrated with 0.01 M HCl solution. pH was monitored with a pH meter and plotted as a function of volume of acid added to make a titration curve. pK a was then found using Gran plot analysis for each replicate.
This procedure was repeated 4 times for each compound.
Partition coefficient determination
The octanol-water partition coefficient (logD) at pH 7.4 was determined using a modified version of the shake flask method. Briefly, PBS (900 µL), 1-octanol (900 µL) and a 10 mg/mL aqueous solution of each compound (2 µL) were added to a 2 mL HPLC vial. The compounds were partitioned between the layers via vortexing and centrifuged at 1,000 g for 1 min to allow for phase separation. A portion (10 µL) was taken from each layer (autoinjector was set up to draw volume at two different heights) and analyzed by HPLC. The relative concentration in each phase was determined by integrating the area under each peak and comparing the ratio of the areas from the octanol and aqueous layers. A calibration curve was performed to ensure that the concentrations detected were within the linear range of the detector. This procedure was repeated 4 times for each compound.
Synthesis of Shaker K + channel RNA
A sample of cDNA clone encoding for Shaker voltage-gated K + channel from D.
melanogaster with inactivation removed 48 was generously provided by the laboratory of Prof. Francisco Bezanilla at The University of Chicago. The DNA was amplified, linearized with Not I enzyme (New England Biolabs, Inc., Ipswich, MA, USA) and transcribed in vitro using the T7 promoter mMESSAGE cRNA kit (Ambion, Austin, Tex., USA).
Expression of Shaker K + channels in Xenopus oocytes
All animal experiments were approved by the University of Guadalajara, CUCEI, with 50 μg/mL gentamycin at pH 7.5.
Recording of K + currents using cut-open voltage clamp
All chemical compounds for this study were acquired from Sigma-Aldrich ( To quantify the effects upon K + currents of 4AP and 4AP analogs, oocytes that successfully expressed the Shaker channel were voltage-clamped in a COVC station.
K + currents were recorded in the same oocyte, first in absence (I K ) and then in presence of each drug (I I ). The voltage-dependence of blocking by 4AP and 4AP analogs was analyzed in terms of the IC 50 as a function of V (IC 50 (V)). IC 50 (V) curves were fitted with a one-step model of inhibition 50, 51 , which allowed to determine the fractional distance through the membrane electrical field (δ) that each 4AP analog has to cross to reach its binding site: Eqn. 2
where IC 50(V = 0) is the value of IC 50 at V = 0 mV, F is the Faraday constant, R is the gas constant, T is the ambient temperature, and z is the apparent charge. Mean values of data ± standard deviation (s.d.) are given or plotted and the number of experiments is denoted by n. The 95% of confidence interval (IC 95 ) is denoted as [Upper limit-Lower limit]; where Upper limit = 10 (log 50 + . ) and Lower limit = 10 (log 50 − . ) .
Results
Basicity and lipophilicity of 4AP analogs
The chemical structures and the abbreviations of the 4AP analogs studied are shown in Figure 2A . Table 1 shows the pK a values of these compounds in order of decreasing basicity. As shown on the table: 4AP, 3Me4AP, and 3MeO4AP are more basic with pK a values higher than 9, while 3F4AP and 3CF 3 4AP are more acidic with pK a values lower than 8. This indicates that the former are mostly protonated at physiological pH, while the latter exist both in the protonated and neutral forms at physiological pH.
In terms of lipophilicity 4AP, 3Me4AP, and 3MeO4AP were found to have octanol/water partition coefficient values at pH 7.4 of - Both pK a and logD trends can be rationalized by the electron-donating or electron-withdrawing nature of the 3-substituent. As the electron-withdrawing strength of the group increases, the dipole of the pyridine nitrogen decreases resulting in a more acidic proton. This lower basicity of the pyridine also results in a greater fraction of the neutral form and higher lipophilicity. A minor deviation from this trend is observed with 3Me4AP. While slightly more basic than 4AP, 3Me4AP is more lipophilic, which can be rationalized by the lipophilic nature of the methyl group compared to a proton in 4AP. Blocking capacity of 4AP analogs K + currents were measured in Xenopus oocytes expressing the commonly studied voltage-gated K + channel Shaker from D. melanogaster. In order to determine the relative blocking capacity, each drug was applied to the same oocyte at increasing concentrations ranging from 1 to 10,000 μM. Then, the relative current was determined as the ratio between the maximal amplitude of the K + current in the absence and in the presence of each drug. Figure 2B shows five representative K + current traces from Shaker elicited at 40 mV, before and after addition of 1,000 μM of each drug. Figure 2C shows the relative current as a function of the concentration of each 4AP analog tested. 
Dependence of the blocking on pH
Since the canonical mechanism describes that only positively-charged molecules can block the channel 41 and protonation of the drug is dependent on the pH, we studied the blocking of the channel (IC 50 ) at pH 6.8, 7.4 and 9.1. To avoid a gradient in pH, both internal and external solutions were replaced.
Panels A to E of Figure 3 show the effects on the relative current as a function of concentration for each 4AP derivative at the different pH values. Interestingly, the analogs with high pK a (4AP, 3Me4AP and 3MeO4AP) showed higher blocking ability (lower IC 50 ) at higher pH, whereas the analogs with lower pK a showed higher blocking ability at lower pH. Since 4AP and derivatives bind from the intracellular side 16 , we hypothesize that in the case of the compounds with high pK a the limiting factor is the permeability of the drug through the oocyte membrane at low pH. In the case of the compounds with low pK a , these drugs are able to permeate through the membrane even at low pH and the limiting factor is the fraction of protonated or active form of the drug. Continuous lines in panels A to E represent the fits with the Hill equation (Eqn. 1). Hill parameters are summarized on Table 2 . 
Dependence of the blocking on voltage
It is known that blocking of K V channels by 4AP involves sequential voltagedependent rearrangements of the protein 31 . During this process, K V channels must
transition to the open conformation before 4AP can bind to its site inside the channel pore. Therefore, it is expected that the blocking of the studied 4AP derivatives will be voltage-dependent as it has been shown for 4AP. For this reason, we studied the IC 50 at several voltage values. We recorded K + currents from Shaker channel in the range of voltage from -100 to 50 mV (see Figure S1 ) and calculated the IC 50 of each drug and voltage as described above. Panels A to E of Figure 4 show the measured relative current as a function of the concentration of each 4AP analog at several voltage values.
For clarity, only representative curves at +10, +30 and +50 mV are shown. From Figure   4 , it can be observed that the calculated IC 50 for each 4AP analog increased with voltage (in μM): from 200 to 350 for 4AP, from 160 to 304 for 3F4AP, from 37 to 50 for 3Me4AP, from 310 to 992 for 3MeO4AP, and from 690 to 1150 for 3CF 3 4AP. These results confirm that blocking of the channel is voltage-dependent and that it is more difficult to block the passage of K + ions at higher voltages than at lower voltages.
Furthermore, this experiment allowed us to calculate the fractional distance through the membrane electrical field that each molecule travels to bind to its site during the experiment 50 . The Woodhull equation (Equation 2 ) describes that the relationship between IC 50 and voltage is dependent on δ. By fitting the IC 50 vs. V curves shown in Figure 4D to the Woodhull equation, we were able to calculate δ for each 4AP analog.
The fitted parameters from this analysis are shown on Table 3 . Since δ values varied between 0.41 and 0.56, we conclude that these molecules have to travel approximately across one half of the membrane electric field. The similarity of the δ values between 4AP and the other derivatives suggests that these drugs share a common binding site. and PET imaging studies in rodent models of MS confirmed the capacity of this compound to detect demyelinated lesions using PET 33, 37 . This compound is in progress to clinical studies and has the potential to advance the imaging of demyelinating diseases.
In PET tracer development, similar to drug development, it is useful to explore multiple derivatives and compare their properties. This process provides confirmation of the target and may result in radioligands with enhanced characteristics. In addition, it is convenient to have 18 F and 11 C versions of the same tracer, as each radiolabeling method provides certain advantages that the other lacks. For example, while 18 F-labeled tracers can be used in sites remote from a cyclotron because of its longer half-life, 11 Clabeled tracers enable multiple scans (be it more than one 11 C-scan or a combination of 11 C/ 18 F-scans) on the same subject and the same day.
Here, we studied the efficiency of blocking K + currents by three novel 4AP analogs, namely: 3-methyl-4-aminopyridine (3Me4AP), 3-methoxy-4-aminopyridine (3MeO4AP), 3-(trifluoromethyl)-4-aminopyridine (3CF 3 4AP) (see chemical structures in Figure 1A ). We selected these compounds as are they are predicted to be permeable to the BBB and are amenable to labeling with 11 C. During our studies, we found that all of these compounds are able to block Shaker (homolog of mammalian K v 1.2) channel albeit with different potency. Specifically, 3Me4AP was found to be ~7 times more potent than 4AP and 3F4AP, whereas 3MeO4AP and 3CF 3 4AP were about 3-4 times less potent. Additionally, we studied the voltage-and pH-dependence of the compounds blocking ability, as these results can provide valuable mechanistic information. From the pH-dependence, we observed that the compounds with lower pK a (i.e., 3F4AP and 3CF 3 4AP) are not active at basic pH, presumably because not enough of the protonated/active form is present. At the same time, the compounds with high pK a (i.e., 4AP, 3Me4AP and 3MeO4AP) are more active at basic pH as it facilitates membrane permeability. Regarding the voltage-dependence, we found that blocking is more effective at lower voltages than at higher voltages, as the voltage provides a greater driving force for the K + ions. From the voltage-dependence analysis, we were able to estimate using the Woodhull equation that these drugs travel about 50 % of the membrane electrical field in order to bind. This is consistent with prior studies about 4AP binding site 16, 29 and strongly suggests that these drugs share a common binding site.
In summary, we have characterized three novel derivatives of 4AP as potential candidates for therapy and imaging. The physicochemical and pharmacological
properties described here will be useful for selecting the compounds with most potential and to explain the differences in terms of kinetics and binding.
